IMUGENE LIMITED — Investor Presentation 2021

Sep 16, 2021

==> picture [116 x 41] intentionally omitted <==

ASX Announcement

Imugene Announces Presentation for Lead Checkpoint Immunotherapy PD1-Vaxx at the ESMO Congress 2021 Annual Meeting

---

SYDNEY, Australia, 17 September 2021: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it is presenting on its PD1-Vaxx cancer checkpoint immunotherapy program at the ESMO Congress 2021 Annual Meeting in Paris.

The presentation is titled ‘IMPRINTER: AN OPEN LABEL, MULTI-CENTER, DOSE ESCALATION/EXPANSION, PHASE I STUDY OF IMU-201 (PD1-VAXX), A B-CELL IMMUNOTHERAPY, IN ADULTS WITH NON-SMALL CELL LUNG CANCER’.

The presentation expands on the study update from 27 August 2021 where it was reported that Imugene had commenced dosing in its final cohort of the monotherapy part of the Phase 1 study. The clinical results continue to indicate that PD1-Vaxx is showing early signs of immune responses in patients, with the development of antibodies to the drug target, PD-1.

Imugene is currently planning to expand the study to combine PD1-Vaxx with standard of care (SOC) therapy in the same lung cancer patient population. This may include a PD-L1 inhibitor or another immunotherapy agent. Inclusion criteria will allow patients that have either progressed on their previous therapy or did not have a response to their SOC and are at high risk of progression to enter the study. Additionally, PD1-Vaxx is currently being evaluated for other tumour indications beyond nonsmall cell lung cancer (NSCLC).

Imugene’s PD1-Vaxx is a B-cell activating checkpoint immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers.

Full study details can also be found on clinical trials.gov under study ID: NCT04432207.

The content of the presentation can be found under Conference Presentations on the Imugene website.

==> picture [527 x 84] intentionally omitted <==

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer info@imugene.com

Investor Enquires

investor@imugene.com

Media Enquires

Matt Wright matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia

2

IMUGENE LIMITED ACN 009 179 551